Alphavirus Replicon Particle Vaccine Breaks B Cell Tolerance and Rapidly Induces IgG to Murine Hematolymphoid Tumor Associated Antigens

Hsuan Su†, Kazuhiro Imai1,2†, Wei Jia1, Zhiguo Li3,4, Rachel A. DiCioccio1, Jonathan S. Serody5,6,7, Jonathan C. Poe1, Benny J. Chen1,4, Phuong L. Doan1,4 and Stefanie Sarantopoulos1,4,8*

1 Department of Medicine, Division of Hematological Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC, United States, 2 Department of Thoracic Surgery, Akita University Graduate School of Medicine, Akita, Japan, 3 Biostatistics and Bioinformatics, Basic Science Department, Duke University Medical Center, Durham, NC, United States, 4 Duke Cancer Institute, Duke University, Durham, NC, United States, 5 Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States, 6 Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States, 7 Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States, 8 Department of Immunology, School of Medicine, Duke University, Durham, NC, United States

De novo immune responses to myeloid and other blood-borne tumors are notably limited and ineffective, making our ability to promote immune responses with vaccines a major challenge. While focus has been largely on cytotoxic cell-mediated tumor eradication, B-cells and the antibodies they produce also have roles in anti-tumor responses. Indeed, therapeutic antibody-mediated tumor cell killing is routinely employed in patients with hematolymphoid cancers, but whether endogenous antibody responses can be incited to blood-born tumors remains poorly studied. A major limitation of immunoglobulin therapies is that cell surface expression of tumor-associated antigen (TAA) targets is dynamic and varied, making promotion of polyclonal, endogenous B cell responses appealing. Since many TAAs are self-antigens, developing tumor vaccines that enable production of antibodies to non-polymorphic antigen targets remains a challenge. As B cell responses to RNA vaccines are known to occur, we employed the Viral Replicon Particles (VRP) which was constructed to encode mouse FLT3. The VRP-FLT3 vaccine provoked a rapid IgG B-cell response to this self-antigen in leukemia and lymphoma mouse models. In addition, IgGs to other TAAs were also produced. Our data suggest that vaccination with RNA viral particle vectors incites a loss of B-cell tolerance that enables production of anti-tumor antibodies. This proof of principle work provides impetus to employ such strategies that lead to a break in B-cell tolerance and enable production of broadly reactive anti-TAA antibodies as potential future therapeutic agents for patients with hematolymphoid cancers.

Keywords: alphavirus replicon particle, hematolymphoid tumor, B cell tolerance, autoantigen, antitumor antibody, VRP, cancer vaccine
INTRODUCTION

Monoclonal antibodies can be utilized to manipulate the immune response to tumors or to directly lead to tumor cell killing, especially when combined with chemotherapy by covalently linking the cytotoxic compounds to antibodies. Importantly, rapidly emerging chimeric antigen receptor (CAR) T cell and CAR NK cell therapies are also extending applications of B cell receptor (BCR) fragments that bind to tumor antigens (1–6). Thus, strategies that induce the active humoral immune response against tumor-associated antigens (TAAs) in the host have also received considerable attention because tumor cell killing is potentially mediated by antibody-dependent cellular cytotoxicity (ADCC) or cross-presentation of antigens to T cells. TAAs may emerge through mutations that lead to new epitopes in self-antigen (7–9). More commonly, TAAs are self-antigens that are either overexpressed or aberrantly expressed normal intracellular molecules. Because normal self-proteins are typically unrecognized by the host immune system unless there is a breach in immune tolerance, producing antibodies to TAA remains a major challenge, especially in tumors that circulate and potentially induce ongoing immune tolerance. If B cell responses to TAAs can be induced and harnessed, they can be used to develop potential therapeutic agents.

During the development of B cells, there is remarkable potential for BCR polyreactivity (10). Autoimmune disease can arise unless B cells with broadly reactive BCRs and the autoreactive antibody production are silenced by ongoing active mechanisms of tolerance that are operational in healthy individuals. In cancer patients, however, immune responses against self-antigens have been found (8). In addition, although many TAAs are self-antigens which are typically poorly immunogenic, antibodies against TAAs have been found in leukemia patients both before and after stem cell transplantation and in a variety of cancers (8, 9, 11–14). The tumor-specific antibodies found in cancer patients have been reported to be associated with better prognosis (9). Studies have also shown that B cells undergo clonal expansion, isotype switching, and affinity maturation within tumor-associated tertiary lymphoid structures (9). These findings further strengthen the role of the B cell response in antitumor immunity and suggest that the antitumor effects of B cells could be augmented through breaking the constraints of immune tolerance toward TAAs (15).

Promoting endogenous immune responses in the host that afford effective tumor eradication or enable development of antibody-based therapies is of potential high impact (16). Venezuelan equine encephalitis virus (VEE) is a positive, single-stranded RNA alphavirus. Packaged replicon particles derived from an attenuated strain of VEE (17, 18) have been used for the development of vaccines for infectious diseases and cancer (19, 20). These VEE replicon particles (VRP) are propagation-defective, but can infect lymphoid cells and have a tropism for dendritic cells (18, 21). They can only undergo one round of infection and are not able to replicate in the host. VRP encoding an inserted gene not only serve as efficient vectors that express the gene of interest in infected cells at high levels (17, 18, 22, 23), they have also been shown to activate both cellular and humoral immune responses against the encoded tumor antigens in murine models of breast tumor (24–27), melanoma (28, 29) and prostate cancer (30, 31). Clinical trials have shown that the VRP vaccines are well-tolerated and are safe to use in patients (32–34). Subsequent trials testing VRP-HER2 vaccines in breast cancer, and VRP-CEA vaccines in colon cancer patients are ongoing (35, 36). Without an inserted gene, VRP have been demonstrated to elicit strong adjuvant activity (21, 37–39). Given what is now known about B-cell activation and autoantibody production that is driven by nucleic acid receptor activation (40, 41), VRP utilization is considered an ideal approach that may provide signals through nucleic acid receptors and facilitate production of antibodies to the TAAs.

Eradication of melanoma utilizing a TAA-encoding VRP was in part mediated via ADCC in an Fc dependent manner (29). These responses do not appear to be impeded by host anti-vector immunity, and notably, repetitive vaccinations with VRP augment the anti-tumor responses (28, 31, 34). Given the efficacy of VRP in solid tumor models, we sought to evaluate the potential of VRP as an approach to vaccination against hematolymphoid malignancies. We chose the fms-like tyrosine kinase-3 (FLT3), a receptor tyrosine kinase that is involved in the proliferation and survival of hematopoietic stem cells and dendritic cells as a model TAA target in our studies. This is in part because studies have shown that FLT3 is highly expressed in most acute leukemias, and the internal tandem duplications (ITD) mutation of this gene that occurs in approximately 25% of AML cases, and increase FLT3 expression on malignant cells has been associated with an adverse prognosis (42, 43). Given the high rate of FLT3 mutations and prognostic impact, FLT3 has been recognized as an attractive target for immunotherapy.

Here we investigated the potency of VRP encoding FLT3 as a therapeutic vaccine in mouse hematolymphoid tumor models. We found that B cell responses against self-antigen FLT3 and other surface antigens expressed on tumor cells were induced in mice with established disease. We reveal the potential of using VRP vaccines in patients with leukemias or lymphomas, especially given that immune responses incited by single-antigen vectors appeared to lead to epitopes/antigen spreading. These findings also have promising intimations for the design of novel antibody-based immunotherapies for hematolymphoid malignancies. Our results warrant further study of VRP and other RNA-based viral particle vaccines in patients with leukemias and lymphomas.

MATERIAL AND METHODS

Animal and Cell Lines
B6.SJL and BALB/c mice were purchased from Taconic Biosciences Inc. (Germantown, NY) and Charles River (Wilmington, MA), respectively. 8- to 12-week-old female mice were used for all experiments. All experiments were performed under a protocol approved by Duke University Institutional Animal Care and Use Committee. C1498 and A20 were purchased from American Type Culture Collection.
Preparation of VRP

The extracellular-transmembrane domain of mouse FLT3 (AA 1 to 584) was cloned into the pVKE plasmid which was provided by Dr. Jonathan S. Serody (University of North Carolina at Chapel Hill, NC). Plasmid with the FLT3 transgene, pVKE-FLT3, or plasmid without the transgene, pVKE-mock, alone with other two helper plasmids encoding the VEE capsid and glycoprotein genes, respectively, were linearized by NotI (NEB) digestion, and T7 mMESSAGE mMACHINE® kit (Ambion) were used for in vitro transcription. Capped VRP transcripts were electroporated into Baby hamster kidney (BHK) cells (ATCC) under a condition of 1000V/100ohms/25uF/3 pulses using ECM® 630 Exponential Decay Wave Electroporation System (BTX) for VRP packaging. The transfected cells were cultured with MEM-α medium (Gibco) containing 10% FBS, 2 mM L-Glutamine, 1 mM sodium pyruvate, MEM non-essential amino acid, 0.055 mM 2-mercaptoethanol, and 400 μg/mL Geneticin™ (Gibco) at 37°C under 5% CO2. The FLT3 expression level on the transfected cells was determined by flow cytometry using fluorochrome-conjugated antibody against mouse FLT3/CD135 (Clone A2F10, BioLegend).

Tumor Challenge and VRP Vaccination

For C1498-FLT3 tumor model, CD45.1 congenic B6.SJL mice were inoculated with 1 x 10^6 C1498-FLT3 cells intravenously via the lateral tail vein. For A20-FLT3 tumor model, BALB/c mice were subcutaneously inoculated with 1 x 10^6 A20-FLT3 cells on the back. Tumor-bearing mice were vaccinated subcutaneously on the rear footpad with 1 - 2.5 x 10^6 IU VRP in a volume of 20 μL PBS on days 4 and 18 post tumor inoculation. A third vaccine was given on day 32 post tumor inoculation in one repeat of the C1498-FLT3 tumor model. Mice in the vehicle control group received PBS only (Figure 1).

The expansion of C1498-FLT3 tumor in the blood of B6.SJL mice was detected using antibodies against mouse CD45.1 (Clone A20, BioLegend) and CD45.2 (Clone 104, BioLegend) by flow cytometry. Mice were monitored and were euthanized when hind limb paralysis or other signs of morbidity were observed to minimize the pain and discomfort. The growth of A20-FLT3 tumor was monitored by measuring two perpendicular diameters using a caliper. Tumor area was calculated according to the following formula: area (mm^2) = length (mm) x width (mm). Mice were monitored and were euthanized when tumors reached an area of approximately 500 mm^2, before reaching any further clinical signs and symptoms, in order to avoid unnecessary pain.

\[
\text{Titration} = \frac{\text{(fraction of infected cell} \times \text{number of cells at time of infection)}}{\text{(volume of the viral stock used for infection)}}.
\]
Flow Cytometric Analysis

For analysis of cell frequency and number in the blood, an equivalent volume of whole blood sample was drawn from the retro-orbital sinus of each mouse, and the blood was transferred immediately to tubes containing heparin (25 U/mL). After lysis of red blood cells with RBC Lysis Buffer (eBioscience), cells were then washed, and non-specific binding to Fc receptors was blocked with TruStain FcX (BioLegend) prior to the surface marker staining. Fluorochrome-conjugated antibodies against CD19 (Clone 6D5, BioLegend), CD4 (Clone GK1.5, BioLegend), CD8a (Clone 53-6.7, BioLegend), CD44 (Clone IM7, BioLegend) and CD62L (Clone MEL-14, BioLegend) were used for B or T cell population analysis. 7-AAD (BioLegend) was used for exclusion of dead cells, and a fixed volume of CountBright Absolute Counting Beads (ThermoFisher Scientific) were used for cell number calculation. Lymphocytes were gated based on the forward and side scatter parameters.

For detection of tumor-binding plasma IgG, 2.5 x 10^5 tumor cells in each test were used. Cells were first stained with LIVE/DEAD™ Fixable Green Dead Cell Stain Kit (ThermoFisher Scientific). After washing, cells were blocked with TruStain FcX™ (BioLegend). Plasma samples from tumor-bearing mice were diluted to adjust the total IgG amount to 1 ug per test according to the result of total IgG ELISA, and were incubated with tumor cells at 4°C for 90 minutes. Cells were washed and followed by staining with 1:200 diluted fluorochrome-conjugated goat anti-mouse IgG antibodies (Clone Poly4053, BioLegend) and anti-mouse CD135 antibody (A2F10, BioLegend) at 4°C for 30 minutes. Stained cells were analyzed on a 3-laser BD FACSCanto II flow cytometer (BD), and the data were further analyzed using the FlowJo software (FlowJo, LLC).

ELISA

Plasma samples were separated from blood by centrifugation at 600 x g/4°C for 10 minutes and were stored at -80°C until used. For plasma IgG determination, goat anti-mouse kappa (Southern Biotech, cat# 1050-01) and goat anti-mouse lambda (Southern Biotech, cat# 1060-01) antibodies were coated on the ELISA plate (Corning) at a total concentration of 2 μg/mL in coating buffer (pH 9.5, BioLegend) overnight at 4°C. Wells were washed with PBS containing 0.1% Tween-20 (PBST) and were blocked with PBST containing 0.5% (w/v) BSA (blocking buffer) at room temperature (RT) for 1 hour. Blocking buffer was also used as dilution buffer. After wells were washed, purified mouse IgG (BIO-RAD, cat# PMP01) was used as a standard in the assay and the plasma samples were serially diluted, and applied to the wells for a 2-hour incubation at RT. Wells were washed and were incubated with 1:5000 diluted HRP-conjugated goat anti-mouse IgG secondary antibody (Southern Biotech, cat# 1030-05) at RT for 1 hour. Wells were washed again, and TMB substrate (Thermo Fisher Scientific) was used according to the manufacturer’s instruction for color development. Reaction was stopped with 2M H2SO4 solution and the absorbance at 450nm was measured with the correction wavelength set at 570 nm. A standard curve with four-parameter logistic curve-fit was generated with GraphPad Prism software, and the IgG concentration of plasma samples was calculated according to the standard curve.

For the anti-FLT3 IgG, IgG1, IgG2b, IgG2c, and IgG3 ELISA, recombinant mouse FLT3 protein (rFLT3, Asn28 – Ser544, Sino Biological Inc.) diluted in coating buffer at a concentration of 2 ug/mL was coated on the ELISA plates overnight at 4°C. Wells were blocked with PBS containing 0.5% casein at RT for 1 hour. Plasma samples were serially diluted and applied to wells for a 2-hour incubation at RT. 1:5000 diluted HRP-conjugated goat anti-mouse IgG (Southern Biotech, cat# 1030-05), anti-mouse IgG1 (Southern Biotech, cat# 1070-05), anti-mouse IgG2b (Southern Biotech, cat# 1090-05), anti-mouse IgG2c (Southern Biotech, cat# 1079-05), or anti-mouse IgG3 (Southern Biotech, cat# 1100-05) was added to wells and incubated at RT for 1 hour. Between each incubation step, wells were washed with PBST. TMB substrate was used for color development as described above. The titration curves of anti-FLT3 plasma IgG were generated with four-parameter logistic curve-fit. Standard curves were generated from serial dilution of monoclonal mouse IgG1(Southern Biotech, cat# 0102-01), IgG2b (Southern Biotech, cat# 0104-01), IgG2c (Southern Biotech, cat# 0122-01), or IgG3 (Southern Biotech, cat# 0105-01). For the standard IgGs, goat anti-mouse kappa (Southern Biotech, cat# 1050-01) and anti-mouse lambda (Southern Biotech, cat# 1060-01) were coated as the capture antibodies. Absorbance values from the linear segment of each plasma dilution curve were used to interpolate the standard curve and calculate the IgG subclass concentration. (O.D value at 1:300 dilution of anti-FLT3 IgG1 and IgG3 ELISAs, and O.D. value at 1:2700 dilution of anti-FLT3 IgG2b and IgG2c ELISAs.)

For the tumor-binding IgG ELISA, membrane protein of C1498-mock cells was extracted using Mem-PER™ Plus Membrane Protein Extraction Kit (ThermoFisher Scientific), and was coated on plate at a concentration of 10 μg/mL in coating buffer (pH 9.5, BioLegend) overnight at 4°C. Wells were blocked with PBS containing 0.5% casein (BIO-RAD) at RT for 1 hour. Plasma samples were serially diluted and applied to the wells for a 2-hours incubation at RT. Wells were incubated with 1:5000 diluted HRP-conjugated goat anti-mouse IgG antibody (SouthernBiotech, cat# 1030-05) at RT for 1 hour. Wells were washed with PBST between each incubation step. TMB substrate was used for color development as described above. The titration curves were generated with four-parameter logistic curve-fit.

Immunoblotting

For the Western blotting, rFLT3 protein (Sino Biological Inc.) was separated on NuPAGE Bis-Tris gel (ThermoFisher Scientific) under reducing conditions and transferred to nitrocellulose membranes using the iBlot system (ThermoFisher Scientific). Membranes were blocked with 1% casein protein in PBS (BIO-RAD) at RT for 1 hour, and were then cut into strips. Strips were incubated with rabbit anti-mouse FLT3 polyclonal IgG (LifeSpan Biosciences, Inc., cat# LS-C6858) or 1:250 diluted plasma samples overnight at 4°C. Strips were washed with PBST and were then probed with 1:15,000 diluted fluorochrome-conjugated antibody
against rabbit IgG (H+L) (LI-COR, cat# 926-68073) or antibody against mouse IgG Fcγ fragment (Jackson ImmunoResearch, cat# 115-655-071) at RT for 1 hour. Strips were washed, rinsed with PBS and imaged by Odyssey infrared imaging system (LI-COR).

For dot blotting, 1 μL of rFLT3 protein diluted to a concentration of 50 ng/ul was spotted on the nitrocellulose membranes in duplicate and was dried on bench top for 6 min. Membranes were then blocked with 1% casein protein in PBS at RT for 1 hour, and were then cut into strips. Strips were incubated with 1:500 diluted plasma samples overnight at 4°C. Strips were washed with PBST and were then probed with fluorochrome-conjugated antibody against mouse IgG Fcγ fragment at RT for 1 hour. Strips were washed, rinsed with PBS and imaged by Odyssey infrared imaging system (LI-COR).

**Statistical Analysis**

Significant differences in cell numbers or frequencies in blood, total IgG concentration, level of tumor antigen-specific IgG and MFI of tumor-binding IgG among experimental groups were determined by ordinary one-way ANOVA or Kruskal-Wallis test (non-parametric one-way ANOVA) as detailed in each figure legend. Significant differences in survival were determined by log-rank test. All statistical analyses were performed with GraphPad Prism software (Version 9.3.1). P-values less than 0.05 were considered significant.

**RESULT**

**VRP-FLT3 Vaccination Induces Robust FLT3-Specific IgG Production in a Mouse Lymphoma Model**

To investigate the ability of VRP vaccines to induce B-cell responses against a self-antigen, a mouse B cell lymphoma model was employed in our study. A20 cells were transfected with plasmid vectors harboring truncated mouse Flt3 gene that contained only the extracellular, transmembrane, and a small part of the intracellular domain of Flt3. FLT3 antigen expression was confirmed by flow cytometry (Supplementary Figure 1) before tumor cells were subcutaneously inoculated on the back of BALB/c mice. FLT3-harboring VRP (VRP-FLT3) vs control VRP (VRP-Ctrl, vector alone) were administered by footpad injection as therapeutic vaccines on days 4 and 18 after tumor challenge. Blood was withdrawn on day 14 and 28 for analyzing the lymphocyte compartment of the tumor-bearing mice. With VRP-FLT3 vaccination, the frequency of lymphocytes was significantly increased (Figure 2A). Among the lymphocytes, an increase of B cell frequency on day 28 was observed only in VRP-FLT3 vaccinated mice (Figure 2B) but not VRP-Ctrl. By contrast, both VRP-FLT3 and VRP-Ctrl vaccinations induced a T cell response and resulted in a significant increase of activated CD44+CD62L− CD8+ T cell frequency (Supplementary Figure 2A).

To examine whether the significant increase in B cell number led to an anti-tumor B cell response after VRP-FLT3 vaccination in our mouse model, we measured antibody production in the tumor-bearing mice. Plasma samples collected on day 28 were analyzed for total IgG concentration, and we found that both VRP-FLT3 and VRP-Ctrl vaccinations significantly increased the total IgG level (Figure 2C). It has been shown that VRP possesses an adjuvant activity and promotes both cellular and humoral immune responses to co-delivered antigen (37, 44). The increase of total IgG in the VRP-Ctrl vaccinated mice could be a virus-related IgG response. To further evaluate the specificity of antibody to FLT3, we performed Western blot and dot blot with the rFLT3 protein. Plasma collected on days 35-42 was tested in Western blot. Only samples from VRP-FLT3 vaccinated mice contained IgG that recognized the recombinant FLT3 protein (Figure 2D). We then used a protein dot blot assay, where the rFLT3 protein remained in a native form, and we found a consistent result. Remarkably, by examining samples collected at early time points, we also found that the FLT3-specific IgG developed rapidly in tumor-bearing mice, as early as 10 days after the first VRP-FLT3 vaccination. Moreover, the titer of FLT3-specific IgG increased by a second vaccination and the response was sustained over time (Figure 2E). These findings suggest that the VRP-FLT3 vaccine induces a rapid IgG antibody response to the model TAA, a self-antigen, and the response can be boosted with repetitive vaccination.

**VRP-FLT3 Vaccination Alters the Composition of Circulating B Cells in a Mouse Lymphoma Model**

To investigate whether VRP vaccination affected certain B cells, we examined the composition of the peripheral B cell compartment using a flow cytometric read-out of serial blood from tumor-bearing mice that received control vs VRP-FLT3 vaccination. Having previously shown that the circulating GL7+ B cells were proportionally increased after alloantigen exposure when B-cell tolerance was lost in mice with chronic graft versus host disease, and production of host tissue-reacting antibodies was promoted (45, 46), we included GL7 in our B cell panel. In the current mouse lymphoma model, we found that the GL7+ B cell frequency was significantly increased in VRP-FLT3 vaccinated mice on day 14 after tumor inoculation (Figure 3A). Since the GL7+ B cell subset from secondary lymphoid organs has a higher capacity for antibody production compared to the GL7− subset after reactivating with the same antigen used for immunization (47), this suggests that antigen-activated GL7+ B cells are incited by VRP vaccination. In addition to the increase of GL7+ B cells, we found a significant elevation of CD93+ transitional-type B cells in the circulation after VRP-FLT3 vaccination by day 14 (Figure 3B), suggesting the B cell compartment was prone to autoreactivity. Moreover, within the CD93+ population, the frequency of IgM+CD23− T1 transitional B cells was also significantly increased (Figure 3C). These data suggest breaking tolerance to self-antigen given that the overexpression of TLR7, an endosomal RNA sensor, was reported to promote the expansion of transitional-type B cells and autoantibody production (48). Taken together, data suggest that production of IgG to anti-self FLT3 induced by the VRP-FLT3 vaccine may reside in the expanded GL7+ or transitional B cell populations.
VRP-FLT3 Vaccination Induces Robust FLT3-Specific IgG Production in Mouse Leukemia Model

To investigate the potential use of VRP vaccines to break B cell tolerance in leukemia, a C1498 mouse leukemia model was employed. C1498 cells were transfected with plasmid vectors harboring truncated mouse Flt3 gene that contained only the extracellular, transmembrane, and a small part of the intracellular domain of Flt3. FLT3 antigen expression on C1498-FLT3 cells was verified (Supplementary Figure 1) before the tumor cells were intravenously injected into B6.SJL mice. VRP-FLT3 or VRP-Ctrl vaccines were administered by footpad injection on days 4 and 18 after inoculation of C1498-FLT3 tumor cells. Peripheral lymphocyte compartments of these mice were then investigated for the immune responses elicited by VRP vaccines. With VRP-FLT3 vaccination, the number of lymphocytes in blood on day 28 was significantly increased (Figure 4A). Within the lymphocyte population, the B cell number in the peripheral blood of VRP-FLT3 vaccinated tumor-bearing mice was increased significantly on day 28 compared to that of the mice receiving PBS or VRP-Ctrl vaccines (Figure 4B). Besides the enrichment of B cells, the frequency of activated CD44+ CD62L- CD4+ T cells and CD44+ CD62L- CD8+ T cells was significantly higher in both VRP-FLT3 and VRP-Ctrl vaccination groups compared to the control mice that received PBS (Supplementary Figure 2B).

While the B cell number in the blood was increased only in VRP-FLT3 vaccinated mice but not the VRP-Ctrl mice on day 28 after tumor inoculation, both VRP-FLT3 and VRP-Ctrl vaccines increased the total IgG level in tumor-bearing mice (Figure 4C). To investigate the production of antibody specific to FLT3 in tumor-bearing mice, we then employed a direct-binding ELISA using a recombinant mouse FLT3 (rFLT3) protein. A significant level of plasma IgG that recognized rFLT3 was detected in mice vaccinated with VRP-FLT3, while this was not observed in VRP-Ctrl vaccinated group (Figures 4D, E). Further investigation of the anti-FLT3 IgG induced by VRP-FLT3 vaccine showed that IgG2b and IgG2c, which are known to mediate ADCC, were the predominant subclasses among the FLT3-specific IgG (Figure 5). Thus, we demonstrated that VRP-FLT3 vaccine is capable of inducing a prompt IgG antibody response to FLT3 in both our lymphoma and leukemia mouse models. These data suggest that VRP-FLT3 can overcome the intrinsic B cell tolerance to self-antigen. In addition, the prevalence of IgG2b and IgG2c subclasses among FLT3-specific IgG hinted at a potential tumor-killing effect of the VRP-FLT3 vaccine through ADCC.
Antibodies Against Tumor Membrane Antigens Are Induced by VRP-FLT3 Vaccination in Mouse Leukemia Model

The production of FLT3-specific IgG induced by VRP-FLT3 vaccine was confirmed by an ELISA using rFLT3. We then applied a flow cytometric approach to investigate the reactivity of plasma antibody to the tumor cells. Target cells used in this flow cytometric assays were the C1498-FLT3 cells or the non-FLT3 expressing C1498-mock cells. The FLT3 expression level of these target cells was confirmed (Supplementary Figure 3). Plasma samples collected on days 35-42 after tumor challenge were diluted according to the total IgG concentration to tailor the IgG amount in each test to 1 µg. Plasma IgG that reacted with tumor cells was detected by a fluorophore-conjugated secondary antibody. As epitope spreading or antigen spreading is observed in autoimmune diseases or cancer research (15, 49–52) and FLT3 is only one of numerous antigens expressed on tumor cells, we also thought to test whether VRP vaccines could elicit antibody responses against antigens other than FLT3. To test binding to other C1498 antigens, we performed the flow cytometric binding test C1498-mock cells as the targets (Figure 6A). Plasma samples from mice that received the VRP-FLT3 vaccination had higher levels of IgG bound to the C1498-mock tumor cells than plasma samples from PBS control mice. To verify this finding, we performed an ELISA with the membrane protein extracts of C1498-mock cells. Membrane protein extracts were coated on the plates, and plasma samples collected on days 35-42 from tumor-bearing mice were titrated and tested. We found that mice vaccinated with VRP-FLT3 developed a significantly higher level of IgG that reacted to tumor membrane proteins other than FLT3 compared to the PBS control mice (Figures 6B, C). These results indicate that VRP-FLT3 vaccinated mice had antibody responses to antigens other than the VRP encoded antigen, FLT3. When C1498-FLT3 cells was used as the target in the flow cytometric assay, plasma samples from VRP-FLT3 vaccinated mice tended to have overall higher reactivity to the C1498-FLT3 tumor cells than plasma samples from mice vaccinated with PBS or VRP-Ctrl (Figure 6D), although statistical significance was...
not reached in this assay, unlike clear demonstration of anti-FLT3 antibody production using purified protein in the FLT3 ELISA (Figure 4E). Together, data suggest that we found binding of IgG to antigen targets beyond the FLT3 model antigen.

**VRP-FLT3 Vaccination Attenuates Growth of Tumor in Both Mouse Lymphoma Model and Leukemia Model**

Since we observed the induction of antibody responses to both FLT3 and other tumor membrane antigens, along with the activation of T cells, we assessed whether our VRP vaccine strategy targeted lymphoma and leukemia in vivo. Remarkably, after VRP vaccine we observed tumor size decrease in the A20-FLT3 tumor model. Tumor inoculated on the back of mice significantly decreased in mice vaccinated with VRP-FLT3 compared to the mice receiving PBS or VRP-Ctrl vaccines (Figure 7A). Likely related to the rapid proliferative capacity of this tumor, the VRP-FLT3 vaccine was unable to completely eliminate the tumor, and there was no survival benefit observed with either VRP-FLT3 or VRP-Ctrl vaccination (Supplementary Figure 4A). Attenuation of tumor growth was also observed in the C1498-FLT3 tumor model. We found an initial decrease in tumor cell number on day 28 after tumor challenge with both VRP-FLT3 and VRP-Ctrl vaccines. Importantly, tumor decrease was maintained at day 35 only in the VRP-FLT3 group although a statistical analysis was not possible since there were only 2 PBS-treated mice alive at day 35 (Figure 7B). Despite the rapid growth rate of C1498, there was also a significant improvement in survival of mice that received the VRP-FLT3 vaccine compared with the PBS control group (Supplementary Figure 4B). These data indicate that VRP vaccination attenuates the expansion of tumor cells in vivo.

**DISCUSSION**

Breaking tolerance to self-antigens is challenging but essential for vaccine approaches targeting TAAs that are recognized as self-antigens by the immune system in the cancer immunotherapy. Previous studies have demonstrated that VRP can induce specific antibodies to TAAs in studies of melanoma, breast cancer and colon cancer (24, 27–29, 34). While induction of T-cell responses with VRP has been reported in both animal and human studies of different solid tumors (27–31, 33–36), and this was also seen in our study, as the frequency of activated T cells increased in the blood of tumor-bearing mice with the VRP vaccinations, VRP is also known...
to elicit a potent humoral response as a vector system for delivering
the antigen of interest or simply as an adjuvant co-administered
with antigens (24, 26, 28, 29, 31, 34, 37, 39, 53). In our study, we
now reveal the capacity of VRP to induce broadly reactive
antibodies to self TAAs in two different hematolymphoid cancer
mouse models. Here we clearly demonstrated that the VRP-FLT3
vaccination overcame the intrinsic self-tolerance mechanisms to
induce a strong antibody response to FLT3 in the tumor-bearing
mice in both of our leukemia and lymphoma models.

VRP encoding the TAA, FLT3, which is a self-antigen known
to be overexpressed in acute leukemias, was given to mice
bearing FLT3-expressing tumors. FLT3 was chosen as the
target antigen in our study for inciting antitumor activity due
to the high correlation between FLT3 and leukemia; however,
there are many other TAAs that have yet to be discovered in
blood cancers. Our study affirmed the reproducible induction of
immune responses to a model self-antigen encoded by VRP, and
we showed that the VRP system can be applied to other newly
discovered tumor antigens or antigens with low immunogenicity
for developing monoclonal antibodies. Antigen/epitope
spreading induced by immunotherapy in cancer treatment has
been reported (15, 50–52). In our study, in addition to the FLT3-
specific antibody, we also found that vaccination of VRP-FLT3
can induce the production of antibodies reacting to the non-
FLT3 expressing C1498-mock cells. The immunity to FLT3
elicited by VRP-FLT3 might serve as a trigger and raise a
subsequent immune response against additional antigens on
the tumor cells. Thus, here we demonstrate for the first time
that VRP encoding FLT3 can promote a polyclonal B cell
response to not only the encoded TAA but also other TAAs
expressed on tumor cells. The observation of antigen/epitope
spreading in our study hinted that the VRP system could
potentially be used as a tool to explore unknown tumor antigens.

Both tumor cells types used in our lymphoma or leukemia
models were aggressive and fast-growing. Thus, in our study,
while the growth of tumors was attenuated by the VPR-FLT3
vaccination in both mouse models, complete tumor regression
was not achieved. Intriguingly, we found prolonged survival in
the leukemia mouse model, associated with a broadened B cell
antibody response elicited by the VRP-FLT3 vaccine. In contrast
ci C1498, the more solid tumor-like A20-FLT3 lymphoma
model may have very different tumor microenvironment from
that of the C1498-FLT3 leukemia model. It has been shown that
the anti-vector immunity to VRP did not hinder the efficacy of
repetitive vaccination with VRP, and development of immunity
to the encoded antigen increased as more VRP vaccinations were
administered (28, 31, 33). Additional doses of VRP-FLT3 vaccine
could potentially further boost and/or maintain the protection
against the tumors in these mouse models. In solid tumor
models, VRP encoding TAA can provide potent tumor
protection in prophylactic settings in studies of melanoma,
breast cancer, and prostate cancer (24, 25, 27–30, 54).

FIGURE 5 | IgG2b and IgG2c are the predominant subclasses of FLT3-specific IgG induced by VRP-FLT3 vaccine. Antigen-specific IgG1 (A), IgG2b (B), IgG2c (C),
and IgG3 (D) responses were detected by ELISA using the recombinant FLT3 as the capture antigen. (A–D) Titration curves of samples was shown. One sample in
PBS and VPR-Ctrl groups was tested, and ten samples in VPR-FLT3 groups were tested. (E) Levels of anti-FLT3 IgG subclasses were compared by calculating
the equivalent IgG subclass concentration using O.D. values at 1:300 dilution of anti-FLT3 IgG1 and IgG3 ELISAs as indicated as the vertical dash line in (A)
and (D), and O.D. values at 1:2700 dilution of anti-FLT3 IgG2b and IgG2c indicated as the vertical line in (B, C) ELISAs. Each symbol represents an individual mouse (n=10).
Bars represent the mean ± SD. Statistical significance were determined by one-way ANOVA, *P<0.05, **P<0.01, ***P<0.001. Data represents one of two
independent experiments.
However, the tumor protecting effect was relatively modest when tumors were established prior to the administration of VRP (29, 54). In some instances, failure in inhibiting the growth of preexisting tumors by VRP vaccine can occur despite the ability of VRP to induce some degree of TAA-specific immune responses (26, 30). One limiting factor in all of these studies, including ours, is the known low efficiency of viral packaging with the VRP system, whereby high titers of vector were not feasible. Technological advances in vaccine strategies with the advent of RNA vaccines will potentially overcome this limitation.

Consistent with our finding, VRP lacking a transgene has been shown to possess an adjuvant activity that promoted the immune response to co-delivered antigen (37, 44, 55). This could account for the increase in frequency of activated T cells in the periphery, and for the increase in total IgG level in serum of mice that received the VRP-Ctrl vaccine in our study. VRP-Ctrl vaccine, despite not encoding a transgene, was able to activate the immune system of tumor-bearing mice, yet it was unable to achieve TAA-specific responses. TAA-specific responses were only observed in tumor-bearing mice that received VRP-FLT3 vaccine, suggesting that a target antigen is needed to incite a desired immunity toward tumor cells. Others have shown that UV inactivation abrogated the adjuvant effect of VRP, indicating that viral RNA and/or the RNA replication plays an important role in triggering the immune responses (37). Several cellular sentinel sensors could be responsible for recognizing the viral replicative molecules (37, 56), and Toll-like receptor 7 (TLR7) is one of the candidates. TLR7 signaling in B cells has been related to activation of autoreactive B cells and induction of autoantibodies (40, 48, 57). Although a preferential infection of DCs and macrophages by VRP has been demonstrated, it has been shown that B cells can also be infected by VRP (21). The critical parameters that mediate the immune activity of VRP have not yet been fully elucidated and the mechanisms of B cell responses induced by VRP remain unclear, but our data suggest that a specific antigen response begets a broader one.

Combining other cancer treatments with VRP vaccine has been shown to yield a synergistic therapeutic activity (26, 54),
indicating a possibility to shape the immune responses and enhance the antitumor efficacy of VRP vaccine. One previous study showed tumor reduction and prolonged tumor-free survival using the VRP-TRP2 vaccine in combination with either antagonist anti-CTLA-4 or agonist anti-GITR immunomodulatory mAb in a melanoma model (54). While checkpoint inhibitor is one of the options for developing new immune therapies, another future strategy may be to administer VRP vaccines in the context of hematopoietic stem cell transplantation (HCT), which still is an important treatment for hematolymphoid malignancies.

Combining autologous HCT (auto-HCT) with a VRP-TAA vaccine strategy to break immune tolerance to tumor antigens warrants further study. Patients with refractory blood cancers are often referred to allogeneic HCT (allo-HCT). Tumor-reacting antibodies were found in patients who underwent allogeneic HCT (14), and an antibody-mediated autoimmune-like syndrome, chronic graft versus host disease (cGVHD) developed after allo-HCT (58, 59), is known to be associated with decreased cancer relapse (60). However, cGVHD is also the main cause of morbidity and mortality in this type of HCT. In contrast, patients who receive auto-HCT do not develop cGVHD, but often encounter tumor relapse. Nevertheless, autologous HCT can be a strategy for delivery of high-dose chemotherapy to patients. It is known that myeloablative treatment before HCT induces a lymphopenia condition in which the B cell compartment reconstitutes in a setting of a high B-cell activating factor (BAFF)-to-B cell ratio and altered B cell homeostasis (61, 62). Our study demonstrated the possibility of provoking immunity to cancers. Applying the VRP-TAA vaccine, which has proven to be an effective treatment to alter self-tolerance, at the right time point after auto-HCT may enable the rescue of those potentially tumor-reactive B cells and augment more efficient anti-tumor immunity without the immune toxicity found after allo-HCT. Our results suggest that future studies addressing how VRP vaccine or other RNA vaccines that promote anti-TAA responses by B cells can be employed as a strategy to develop antibody therapies.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

The animal study was reviewed and approved by Institutional Animal Care and Use Committee of Duke University.

AUTHOR CONTRIBUTIONS

SS conceptualized and supervised the study. SS, WJ, JP, and KI designed the experiments. WJ, KI, HS, and RD performed experiments and acquired data. KI and HS analyzed and interpreted results. ZL performed the statistical analysis. JS provided technical and material support. HS and SS wrote the manuscript. JP, BC and PD provided scientific advice and reviewed the paper. All authors contributed to the article and approved the submitted version.

FUNDING

This work was funded by the Department of Defense, Congressionally Mediated Research Program W81XWH1-8-1-0239 (CA171068).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.865486/full#supplementary-material
REFERENCES

1. Weiner LM, Bhodapkar NV, Ferrone S. Monoclonal Antibodies for Cancer Immunotherapy. *Cancer* (2009) 103(9):9968-1003. doi: 10.1001/jama.2009.1003

2. Weiner LM, Corella R. Monoclonal Antibodies: Versatile Platforms for Cancer Immunotherapy. *Nat Rev Immunol* (2010) 10(5):317-27. doi: 10.1038/nri2744

3. Barrett AJ, Le Blanc K. Immunotherapy Prospects for Acute Myeloid Leukemia. *Crit Rev Oncol Hematol* (2016) 97:72-84. doi: 10.1016/j.critrevonc.2015.08.014

4. Tesh RD, Choppin PW, Lennette ET. A Review of Monoclonal Antibody Therapies in Lymphoma. *Cancer Res* (2000) 60(11):3459-63. doi: 10.1158/0008-5472.CAN-00-1052

5. Johnson LA, June CH. Driving Gene-Engineered T Cell Immunotherapy of Cancer. *Cell* (2017) 27(1):38-58. doi: 10.1016/cr.2016.154

6. Mehta RS, Rezvani K. Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer. *Front Immunol* (2018) 9:283. doi: 10.3389/fimmu.2018.00283

7. Finn OJ. Cancer Immunology. *N Engl J Med* (2008) 358(25):2704-15. doi: 10.1056/NEJMra072379

8. Reuschenbach M, von Knebel Doeberitz M, Wentrup M. A Systematic Review of Humoral Immune Responses Against Tumor Antigens. Cancer *Marrow Transplantation* (2009) 58(10):1355-44. doi: 10.1007/s10956-009-0733-1

9. Sharov GV, Serebrovskaya EO, Yuzhakova DV, Britanova OV, Chudakov DM. B Cells, Plasma Cells and Antibody Repertoires in the Tumour Microenvironment. *Nat Rev Immunol* (2020) 20(5):294-307. doi: 10.1038/s41577-019-0257-x

10. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant Autoantibody Production by Early Human B Cells Precursors. *Science* (2003) 301(5638):1374-7. doi: 10.1126/science.1086907

11. Wu CJ, Yang XF, McLaughlin S, Neuberg D, Canning C, Stein B, et al. Alphavirus Vector-Transduced Dendritic Cells Are Successful Therapeutic Vaccines Against Neu-Overexpressing Tumors in Wild-Type Mice. *Vaccine* (2007) 25(36):6604-12. doi: 10.1016/j.vaccine.2007.06.058

12. Nelson EL, Prieto D, Alexander TG, Pushko P, Lotfs LA, Rayner JO, et al. Venezuelan Equine Encephalitis Virus Replication Overcomes Intrinsic Tolerance and Elicits Effective Anti-Tumor Immunity to the Self Tumor-Associated Antigen, Neu in a Rat Mammary Tumor Model. *Breast Cancer Res Treat* (2003) 82(3):169-83. doi: 10.1023/B:BERA.0000004733.09678.bb

13. Luast AK, Sur BW, Wang K, Hubby B, Smith JF, Nelson EL. VRP Immunotherapy Targeting Neu: Treatment Efficacy and Evidence for Imunoediting in a Stringent Rat Mammary Tumor Model. *Breast Cancer Res Treat* (2007) 106(3):371-82. doi: 10.1007/s10549-007-9517-8

14. Burgents JE, Moran TP, West ML, Davis NL, Johnston RE, Serody JS. The Immunosuppressive Tumor Environment Is the Major Impediment to Successful Therapeutic Vaccination in Neu Transgenic Mice. *J Immunother* (2010) 33(5):482-91. doi: 10.1016/j.jimm.2010.06.008

15. Wang X, Wang JP, Maughan MF, Lachman LB. Alphavirus Replicon Particles Containing the Gene for HER2/Neu Inhibit Breast Cancer Growth and Tumor Vaccination with HER2/Neu-Specific Alphavirus Replicon Particles. *J Virol* (2007) 81(10):5184-5. doi: 10.1128/JVI.01866-06

16. Goldberg SM, Bartido SM, Gardner JP, Guevara-Patino JA, Montgomery SC, Perales MA, et al. Comparison of Two Cancer Vaccines Targeting Tyrosinase: Plasmid DNA and Recombinant Alphavirus Replicon Particles. *Clin Cancer Res* (2005) 11(22):8114-21. doi: 10.1158/1078-0432.CCR-05-1410

17. Avogadri F, Merghoub T, Maughan MF, Hirschhorn-Cymerman D, Morris J, Ritter E, et al. Alphavirus Replicon Particles Expressing TRP-2 Provide Potent Therapeutic Effect on Melanoma Through Activation of Humoral and Cellular Immunity. *Ploto* (2010) 7(9):e2670. doi: 10.1371/journal.pone.0012670

18. Garcia-Hernandez MDL, Gray A, Hubby B, Kast WM. In Vivo Effects of Vaccination With Six-Transmembrane Epithelial Antigen of the Prostate: A Candidate Antigen for Treating Prostate Cancer. *Cancer Res* (2007) 67(3):1341-51. doi: 10.1158/0008-5472.CAN-06-2996

19. Durso RJ, Andjelic S, Gardner JP, Margitich DJ, Donovan GP, Arrigale RR, et al. A Novel Alphavirus Vaccine Encoding Prostate-Specific Membrane Antigen Elicits Potent Cellular and Humoral Immune Responses. *Clin Cancer Res* (2007) 13(13):3999-4008. doi: 10.1158/1078-0432.CCR-06-2202

20. Slovin SF, Kehoe M, Durso R, Fernandez C, Olson W, Gao JP, et al. A Phase I Dose Escalation Trial of Vaccine Replicon Particles (VRP) Expressing Prostate-Specific Membrane Antigen (PSMA) in Subjects With Prostate Cancer. *Vaccine* (2013) 31(6):676-85. doi: 10.1016/j.vaccine.2012.11.096

21. Bernstein DI, Niedzwiecki D, Rittinger K, Watson A, Smith K, Norberg P, et al. Clonal Evolution of Autoreactive Germinal Centers. *Cell* (2017) 170(5):913-26.e19. doi: 10.1016/j.cell.2017.07.026

22. Wang Y, Zhang Z, Luo J, Han X, Wei Y, Wei X. Mrna Vaccine: A Potential Therapeutic Strategy. *Mol Cancer* (2021) 20(1):33. doi: 10.1186/s12943-021-01311-z

23. Pushko P, Parker M, Ludwig GV, Davis NL, Johnston RE, Smith JF. Replicon-Helper Systems For Attenuated Venezuelan Equine Encephalitis Virus: Expression of Heterologous Genes In Vitro and Immunization Against Heterologous Pathogens In Vivo. *Virology* (1997) 239(2):389-401. doi: 10.1006/viro.1997.8878

24. MacDonald GH, Johnston RE. Role of Dendritic Cell Targeting in Venezuelan Equine Encephalitis Virus Pathogenesis. *J Virol* (2000) 74(2):914-22. doi: 10.1128/JVI.74.2.914-922.2000

25. Rayner JO, Dryga SA, Kamrud KI. Alphavirus Vectors and Vaccination. *Rev Med Virol* (2002) 12(5):279-96. doi: 10.1002/rmv.360

26. Lundstrom K. Alphavirus-Based Vaccines. *Viruses* (2014) 6(6):2392-415. doi: 10.3390/v6062392

27. Tonkin DR, Jorquera P, Todd T, Beard CW, Johnston RE, Barro M. Alphavirus Replicon-Based Enhancement of Mucosal and Systemic
Immunity Is Linked to the Innate Response Generated by Primary Immunization. *Vaccine* (2010) 28(18):3238–46. doi: 10.1016/j.vaccine.2010.01.066.

39. Khalid SM, Tonkin DR, Sneed AT, Parks GD, Johnston RE, White LJ. An Alphavirus-Based Adjuvant Enhances Serum and Mucosal Antibodies, T Cells, and Protective Immunity to Influenza Virus in Neonatal Mice. *J Virol* (2014) 88(16):9182–96. doi: 10.1128/JVI.00327-14.

40. Suthers AN, Sarantopoulos S. TLR7/TLR9- and B Cell Receptor-Signaling Crosstalk: Promotion of Potentially Dangerous B Cells. *Front Immunol* (2017) 8:775. doi: 10.3389/fimmu.2017.00775.

41. Nundel K, Green NM, Shaffer AL, Moody KL, Busto P, Eilat D, et al. Cell-Intrinsic Expression of TLR9 in Autoreactive B Cells Constrains BCR/TLR7-Dependent Responses. *J Immunol* (2015) 194(6):2504–12. doi: 10.4049/jimmunol.1402425.

42. Small D. Targeting FLT3 for the Treatment of Leukemia. *Leukemia* (2009) 23(5):930–8. doi: 10.1038/leu.2009.128.

43. Daver N, Schlenk RF, Russell NH, Levis MJ, et al. Targeting FLT3 Mutations in AML: Review of Current Knowledge and Evidence. *J Immunol* (2014) 192(2):680–7. doi: 10.4049/jimmunol.1201572.

44. Thompson JM, Whitmore AC, Staats HF, Johnston RE. Alphavirus Replicon Particles Acting as Adjuvants Promote CD8+ T Cell Responses to Co-Delivered Antigen. *Vaccine* (2008) 26(33):4267–75. doi: 10.1016/j.vaccine.2008.05.046.

45. Jia W, Peirce JC, Su H, Anand S, Matsumiya GK, Rathmell JC, et al. BAFF Promotes Heightened BCR Responsiveness and Manifestations of Chronic GVHD After Allogeneic Stem Cell Transplantation. *Blood* (2021) 137(18):2544–57. doi: 10.1182/blood.2020008040.

46. Poe JC, Jia W, Di Paolo JA, Reyes NJ, Kim JY, Su H, et al. SYK Inhibitor Entospletinib Prevents Ocular and Skin GVHD in Mice. *Blood* (2011) 118(24):e122430. doi: 10.1182/blood-2011-01-325266.

47. Cervenak L, Magyar A, Boja R, Laszlo G. Differential Expression of GL7 Receptor/Toll-Like Receptor 7 Engagement. *J Exp Med* (2005) 202(9):1171–82. doi: 10.1084/jem.20041070.

48. Giltiay NV, Chappell CP, Sun X, Kolhatkar N, Teal TH, Wiedeman AE, et al. RNA-Associated Autoantigens Activate B Cells by Combined B Cell Antigen Receptor/Toll-Like Receptor 7 Engagement. *J Exp Med* (2005) 202(9):1171–7. doi: 10.1084/jem.20050630.

49. Tobon GJ, Izquierdo JH, Canas CA. B Lymphocytes: Development, Tolerance, and Their Role in Autoimmunity–Focus on Systemic Lupus Erythematosus. *Autoimmune Dis* (2013) 2013:827254. doi: 10.1155/2013/827254.

50. Corbiere V, Chapiro J, Stroobant V, Ma W, Lurquin C, Lethé B, et al. Antigen Spreading Contributes to MAGE Vaccination-Induced Reduction of Melanoma Metastases. *Cancer Res* (2011) 71(4):1253–62. doi: 10.1158/0008-5472.CAN-10-2693.

51. Gullery JL, Madan RA, Pachyński R, Mulders P, Sheikh NA, Trager J, et al. Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment. *J Natl Cancer Inst* (2017) 109(4):djw261. doi: 10.1093/jnci/djw261.

52. Amos SM, Duong CP, Westwood JA, Ritchie DS, Junghans RP, Darcy PK, et al. Autoimmunity Associated With Immunotherapy of Cancer. *Blood* (2011) 118(3):499–509. doi: 10.1182/blood-2011-01-325266.

53. Osada T, Berglund P, Morse MA, Hubby B, Lewis W, Niedzwiecki D, et al. Co-Delivery of Antigen and IL-12 by Venezuelan Equine Encephalitis Virus Replicon Particles Enhances Antigen-Specific Immune Responses and Antitumor Effects. *Cancer Immunol Immunother* (2012) 61(11):1941–51. doi: 10.1007/s00262-012-1248-x.